Aclaris Therapeutics (ACRS)

Trade ACRS now with
8/3/2018 7:09:02 AM Aclaris Therapeutics Q2 Net Loss Widens To $31.2 Mln Or $1.01/shr From $14.9 Mln Or $0.56/shr Last Year
7/9/2018 7:03:27 AM FDA Grants Fast Track Designation To Aclaris Therapeutics’ Investigational JAK Inhibitor For Alopecia Areata
6/26/2018 7:04:13 AM Aclaris Therapeutics Announces First Patient Dosed In A Phase 2 Clinical Trial Of ATI-501 Oral Suspension
4/6/2018 7:02:53 AM Aclaris Therapeutics Partners With Cipher Pharma To Seek Regulatory Approval & Commercialize A-101 40% Topical Solution
3/19/2018 8:09:02 AM Aclaris Therapeutics Says Positive Update On Phase 2 Results After A 3-month Follow-Up Of A-101 45% Topical Solution
3/12/2018 7:10:27 AM Aclaris Therapeutics Q4 Net Loss $22.9 Mln Vs Loss $11.5 Mln Last Year
1/8/2018 7:20:49 AM Aclaris: A-101 45% Topical Solution Meets Primary, Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts
1/7/2018 9:50:22 AM New Drugs Approved In December
12/15/2017 7:05:15 AM Aclaris Therapeutics Gets FDA Approval For ESKATA Topical Solution, 40% (w/w) For Raised Seborrheic Keratoses
12/7/2017 6:07:29 AM Epidarex Capital Portfolio Company, Harpoon Medical Acquired By Edwards Lifesciences For Up To $250 Mln
11/7/2017 7:14:30 AM Aclaris Therapeutics Q3 Net Loss $18.2 Mln, Revenue $0.7 Mln
9/19/2017 8:06:12 AM Aclaris Therapeutics Announces Publication Of Data From Phase 2 Clinical Trial Of A-101 Topical Solution For SK
9/5/2017 8:14:39 AM Aclaris Therapeutics Announces Issuance Of Two U.S. Patents Covering JAK Inhibitors For Treating Hair Loss Disorders
8/8/2017 7:20:18 AM Aclaris Therapeutics Q2 Net Loss $14.8 Mln Or $0.56/shr Vs Loss $12.9 Mln Or $0.62/Shr Last Year
8/2/2017 8:09:26 AM Aclaris Therapeutics Submits Investigational NDA For ATI-50002 To Treat Alopecia Areata
6/29/2017 8:06:28 AM Aclaris Therapeutics Initiates Phase 2b Clinical Trials Of A-101 For Topical Treatment Of Common Warts
3/15/2017 7:05:25 AM Aclaris Therapeutics Q4 Loss Per Share $0.49 Vs Loss $0.28 Last Year